The GNPDA1 Knouckout Jurkat Polyclonal Cells are a CRISPR/Cas9-mediated gene-edited polyclonal cell population targeting glucosamine-6-phosphate deaminase 1 (GNPDA1) in the Jurkat human T lymphocyte line. This knockout model provides a loss-of-function system to investigate the hexosamine biosynthetic pathway and its crosstalk with glycolysis and O-GlcNAcylation signaling in a T-cell leukemia context. The polyclonal nature ensures representation of diverse editing events, offering a robust population-level phenotype for functional genomics and metabolic studies.
The Jurkat host cell line is an immortalized human T lymphocyte model derived from an adolescent male with acute lymphoblastic leukemia. Widely employed to study T-cell receptor signaling, activation, and apoptosis, Jurkat cells serve as a foundational model in immunology and leukemia research. Their rapid proliferation and well-characterized signaling networks make them ideal for dissecting metabolic dependencies that govern malignant T-cell biology.
GNPDA1 catalyzes the reversible deamination of glucosamine-6-phosphate to fructose-6-phosphate, a pivotal step that channels amino sugar metabolites into glycolysis and modulates levels of UDP-GlcNAc, the obligate substrate for O-GlcNAc transferase (OGT)-mediated protein O-GlcNAcylation. The enzyme operates within the hexosamine biosynthetic pathway downstream of glutamine and glucose uptake, influenced by mTORC1 signaling. It functionally interacts with hexokinase (HK), glucose transporters (GLUTs), and glutamine:fructose-6-phosphate amidotransferase (GFPT), and feeds fructose-6-phosphate into glycolysis while controlling O-GlcNAc modification of numerous signaling proteins.
In Jurkat leukemia cells, disruption of GNPDA1 dismantles the hexosamine-glycolysis interface. According to the known mechanistic framework, GNPDA1 knockout depletes UDP-GlcNAc availability and attenuates global protein O-GlcNAcylation, consequently rerouting glycolytic flux and potentially impairing T-cell receptor-driven proliferation and survival programs. This creates a powerful isogenic model to define how GNPDA1-dependent metabolic regulation shapes leukemic T-cell fitness, apoptosis sensitivity, and signal transduction.
Researchers can employ these polyclonal knockout cells in a variety of advanced assays: Western blotting with O-GlcNAc-specific antibodies for monitoring glycosylation changes, LC-MS/MS metabolomics to quantify hexosamine and glycolytic intermediates, Seahorse metabolic flux analysis for real-time measurement of glycolysis and mitochondrial respiration, MTS-based proliferation assays to assess growth dependency, flow cytometric evaluation of apoptosis via Annexin V/PI staining, and RNA sequencing for transcriptomic profiling following GNPDA1 loss. Additional applications include cancer metabolism research, T-cell activation studies, hexosamine pathway dissection, drug target identification, and investigation of metabolic reprogramming in leukemia. For further information or to discuss experimental design, please contact Ascent Research.
